Oncology

Protein found to play vital role in development of disease.

Researchers find 23 new prostate cancer risk sites on the genome.

Baldness on front and crown of head linked to increased chance of developing aggressive prostate cancer.

A prognostic disease marker that often occurs in patients with triple-negative breast cancer may lead to development of a medication to close a therapeutic gap in targeted cancer treatment.

The FDA has expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

Regina, a licensed pharmacist for more than 20 years, developed breast cancer at 48 years of age.

A recent meta-analysis published in the journal Plos One indicates a potential link between breast cancer and use of a common blood pressure medication, but a closer look tells a different story.

Pembrolizumab is the first drug approved that blocks the PD-1 cellular pathway.

Medicaid beneficiaries are more likely to be screened for 3 types of cancer in states where physicians receive higher payments for office visits, a study suggests.

Specialty therapies for rheumatoid arthritis, multiple sclerosis, and breast cancer tended to have positive functional and clinical outcomes for patients.

Investigators in Europe have confirmed the effectiveness of prostate-specific antigen screening in reducing the risk of cancer-related mortality and in detecting a larger share of prostate cancer cases.

Following favorable results of the ASPIRE clinical trial, Amgen acquired Onyx Pharmaceuticals for an estimated $9.7 billion.

The device could make more donated lungs available for transplant.

A phase 2 trial reported 100% 3-year overall survival rates with frontline therapy consisting of lenalidomide, bortezomib, and dexamethasone in younger patients with multiple myeloma.

The FDA today approved the first non-invasive colorectal screening test to indicate the presence of certain abnormal growths that may be colorectal cancer or precursors to colon cancer.

Screening of newborn children for hepatitis C and new, more effective hepatitis C treatments may virtually eliminate the disease in the United States by 2036.

More than 90% of women in the program received timely follow-up care.

In a study that has the potential to change public health recommendations for breast cancer screening, researchers have validated the value of mammography in older women.

More than 90% of women in the program received timely follow-up care.